Researchers propose that an infusion of memory T cells from people who have recovered from SARS-CoV-2 infections could treat severe disease.

As the first clinical data become available on treating coronavirus patients with the cells, scientists are equivocal about the rationale for the intervention.

The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.

To advance the possibility of off-the-shelf cardiac cell therapies, scientists devise an engineered cardiac stem cell that avoids stimulating a detrimental immune attack.

Several early-stage clinical trials indicate that implanting patients with the cells is safe. But whether they can alleviate neurological problems remains to be seen.

The decision may facilitate the agency cracking down more effectively on the unproven interventions these companies sell.

Uncertainties about the cells’ risk profiles and the potential for hyping unproven therapies mean scientists and the media must tread carefully.

From disastrous scientific setbacks to the upending of scientific dogma and the end of a 40-year search for a protein

It’s the latest fallout from an investigation by Harvard and Brigham and Women’s into work overseen by Piero Anversa.

Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.

This is the first time researchers have tested the use of the reprogrammed stem cells in the human brain.

A trial to test whether so-called c-kit cardiac stem cells, first reported by Piero Anversa, could help patients with chronic heart failure has been halted in light of suspicion surrounding his work.

Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.